|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: acyclovir
Summary for Generic Name: acyclovir
| |||||||||||||||
Clinical Trials for: acyclovirEffect of Body Mass on Acyclovir Pharmacokinetics Status: Recruiting Condition: Hematological Malignancy; Pharmacokinetics of Acyclovir A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation Status: Active, not recruiting Condition: Genital Herpes A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) Status: Completed Condition: Herpes Simplex Virus; Neonatal Sepsis Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS) Status: Completed Condition: Herpes Simplex; HIV Infections HSV-2 Shedding Resolution After Acyclovir Treatment Status: Completed Condition: Genital Herpes Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates Status: Completed Condition: Herpes Simplex Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth Status: Completed Condition: Herpes Simplex Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2) Status: Completed Condition: HIV Infections; Herpesvirus 2, Human Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Status: Recruiting Condition: Meniere's Disease A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes Status: Completed Condition: HIV Infections; HIV Seronegativity; Herpes Genitalis Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||||||
Litigation for: ACYCLOVIR | |||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Valeant Bermuda | XERESE | acyclovir; hydrocortisone | CREAM; TOPICAL | 022436 | Jul 31, 2009 | RX | Yes | <disabled> | NEW COMBINATION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Valeant Bermuda | XERESE | acyclovir; hydrocortisone | CREAM; TOPICAL | 022436 | Jul 31, 2009 | RX | Yes | 7,223,387 | Y | <disabled> | NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Valeant Bermuda | XERESE | acyclovir; hydrocortisone | CREAM; TOPICAL | 022436 | Jul 31, 2009 | RX | Yes | RE39264 | Y | <disabled> | NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Valeant Bermuda | XERESE | acyclovir; hydrocortisone | CREAM; TOPICAL | 022436 | Jul 31, 2009 | RX | Yes | 6,514,980 | Y | <disabled> | NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc